According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...

Lentiviral vectors (LVVs) have proven to be extremely versatile genetic delivery vehicles, gaining space as a gene transfer technology tool used both for cell and gene therapies. They are utilised for ...

Vyriad announced $25M final tranche of its Series B to support the first-in-human testing of VV169, Vyriad’s in vivo CAR-T ...

Francesca Vitelli and Orla Cloak from Minaris with Matthew Durdy, Eytan Abraham, and Dan Gibson of CGT Catapult.

T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase ...

PERSEUS trial findings suggest that modern myeloma therapies could lead to survival rates similar to age-matched controls. KLN-1010, an off-the-shelf gene therapy, demonstrated promising MRD-negative ...

AcouSort AB today announced it has entered a collaboration with MFX, a UK-based developer of next-generation scalable bioreactor platforms, to evaluate if AcouSort's technology can be paired with MFX' ...

Minaris will move its center for viral vector innovation to occupy space within CGT Catapult’s collaborator laboratories in London and will work with CGT Catapult on the further development of ...

Testosterone promotes the conversion of glucose to fatty acids by increasing the expression of ACLY in seminal vesicle epithelial cells, thereby regulating the seminal plasma components.

VV169 saw complete clearance of disseminated myeloma tumors within 28 daysAnother dataset highlights Vyriad’s work in improved vector retargeting strategies in a comparative study of three methods for ...

GERMANTOWN, MD AND CHICAGO, IL / ACCESS Newswire / December 16, 2025 / uBriGene Biosciences, a leading global lentivirus CDMO ...

Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) is one of the stocks that will double in 2026. Earlier on November 18, BofA ...